丽珠医药(01513):莱康奇塔单抗注射液被纳入优先审评审批程序

智通财经
Jan 07

智通财经APP讯,丽珠医药(01513)发布公告,丽珠医药集团股份有限公司Livzon Pharmaceutical Group Inc.*(本公司)控股子公司珠海市丽珠单抗生物技术有限公司(丽珠单抗)与北京鑫康合生物医药科技有限公司联合开发的产品莱康奇塔单抗注射液(本品)于2025年12月26日被国家药品监督管理局药品审评中心纳入拟优先审评品种公示名单;现公示期满后,根据国家药品监督管理局药品审评中心网站信息公开显示,本品已纳入优先审评品种名单,正式进入药品上市许可优先审评审批程序。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10